# Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

> **NCT02436993** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of California, Irvine** · enrollment: 120 (actual)

## Conditions studied

- Breast Carcinoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Bevacizumab
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT02436993
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-04
- **Primary completion:** 2023-11
- **Final completion:** 2036-12
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02436993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02436993, "Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02436993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*